| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$146 |
2025 - Corporate Governance and Appendix 4G
|
26 Feb 2026 8:38AM |
$0.800 |
$1.160 |
risen by
45%
|
|
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$28 |
H1 FY26 Financial Results Presentation
|
26 Feb 2026 8:38AM |
$0.595 |
$0.180 |
fallen by
69.75%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Group Revenue for Trajan Group Holdings Limited in H1 FY26 was $84.1M, an increase of 3.8% from the previous period.
- The Group's nEBITDA decreased by 36.2% to $5.0M.
- Net Revenue for the Components & Consumables segment was $51.9M, up 6.1%.
- Capital Equipment segment saw a decline in Net Revenue by 2.7% to $29.1M.
- Disruptive Technologies segment grew significantly with Net Revenue increasing by 40.2% to $3.1M.
- The company faced margin enhancement delays due to inefficiencies and set-backs in establishing 'in region for region' capabilities.
- FY2026 revenue guidance is set at $170.0M+, with Group nEBITDA anticipated at $16.0M+.
- Challenges included macroeconomic environment, tariff volatility, and geopolitical unrest.
- Positive indicators for H2 include expected growth in Pharma and recovery in Capital Equipment orders.
- Trajan aims to enhance profitability through Project Neptune and pricing actions in H2.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Truscreen Group Limited (TRU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Health Care |
$13 |
Results Guidance FY2026
|
26 Feb 2026 8:38AM |
$0.015 |
$0.012 |
fallen by
20%
|
|
TRU - Price-sensitive ASX Announcement
Full Release
Key Points
- FY2026 product sales revenue expected to be NZ$2.4 million
- Total revenue for FY2026 expected to be approximately NZ$2.7 million
- Expected net loss of ~NZ$2.2 million for FY2026
- Investment in expanding distributor network in Uzbekistan, India, Indonesia, and African markets
- Recent clinical study results increased interest in TruScreen technology
- Reduced Australian R&D tax refund due to lower expenditure
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$28 |
H1 FY26 Financial Results Release
|
26 Feb 2026 8:38AM |
$0.595 |
$0.180 |
fallen by
69.75%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Group net revenue for H1 FY26 was $84.1M, up 3.8% from the previous corresponding period.
- Normalized EBITDA decreased by 36.2% to $5.0M.
- Components & Consumables segment revenue increased by 6.1% to $51.9M.
- Capital Equipment segment revenue decreased by 2.7% to $29.1M.
- Disruptive Technologies segment revenue increased by 40.2% to $3.1M.
- Net debt increased by $2.7M to $32.2M as of December 31, 2025.
- $12.8M in cash was reported at the end of December 2025.
- FY26 net revenue is expected to exceed $170.0M.
- FY26 group normalized EBITDA is projected to exceed $16.0M.
- CEO Stephen Tomisich highlighted strategic efforts for future margin growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| COG Financial Services Limited (COG) ORDINARY FULLY PAID |
Financials |
$344 |
Appendix 4D & Half Year Financial Report
|
26 Feb 2026 8:37AM |
$1.565 |
$1.615 |
risen by
3.19%
|
|
COG - Price-sensitive ASX Announcement
Full Release
Key Points
- COG Financial Services Limited reported a 14% increase in underlying profit after tax attributable to members of the Group.
- Revenue from continuing operations increased by 8.6% compared to the previous period.
- Net profit from continuing operations after tax attributable to members rose by 16.7%.
- Basic and diluted earnings per share from continuing operations were 4.80 cents.
- The Group's net asset position was $201,526k as of 31 December 2025.
- Cash flows from operating activities amounted to $39,836k, reflecting a strong operational cash inflow.
- The Broking & Aggregation segment saw a 3% rise in revenues.
- Salary Packaging segment's revenues increased by 41% due to organic growth and acquisitions.
- The Directors declared an interim dividend of 3.5 cents per share for the period ended 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atturra Limited (ATA) ORDINARY FULLY PAID |
Information Technology |
$144 |
Atturra H1 FY26 Accounts
|
26 Feb 2026 8:37AM |
$0.575 |
$0.390 |
fallen by
32.17%
|
|
ATA - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities increased by 27.8% to $180,558,000.
- Underlying EBITDA fell by 46% to $7,326,000.
- Underlying EBIT decreased by 79.6% to $1,900,000.
- Loss after tax for the half-year was $4,001,000.
- No dividends were paid, recommended, or declared.
- Significant share buybacks and acquisitions affected cash flow.
- Management emphasized Underlying EBITDA as a crucial financial metric.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QuickFee Limited (QFE) ORDINARY FULLY PAID |
Financials |
$30 |
Change of Directors Interest Notice - Bruce Coombes
|
26 Feb 2026 8:35AM |
$0.079 |
$0.078 |
fallen by
1.27%
|
|
| ReadyTech Holdings Limited (RDY) ORDINARY FULLY PAID |
Information Technology |
$185 |
Half Year Accounts - Investor Presentation
|
26 Feb 2026 8:35AM |
$1.730 |
$1.500 |
fallen by
13.29%
|
|
RDY - Price-sensitive ASX Announcement
Full Release
Key Points
- ReadyTech's FY26 half-year revenue increased by 5.6% to $61.6 million.
- Workforce division's growth driven by flagship products offsetting churn.
- Strategic investments in R&D emphasize flagship products and AI capabilities.
- Challenges include elevated churn in mature products and delayed P&L impacts.
- The company maintains a strong balance sheet for financial flexibility.
- Revised FY26 revenue guidance is set at $125-127 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Trajan Group Holdings Limited (TRJ) ORDINARY FULLY PAID |
Health Care |
$28 |
H1 FY26 Appendix 4D and Interim Report
|
26 Feb 2026 8:35AM |
$0.595 |
$0.180 |
fallen by
69.75%
|
|
TRJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 3.8% to $84,059,000.
- Net loss was $449,000, a decline of 87.5%.
- Comprehensive loss was $2,703,000.
- No dividends declared or proposed.
- Total equity decreased to $103,050,000.
- No acquisitions or losses of entities, associates, or joint ventures.
- Detailed financial statements and auditor's review included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReadyTech Holdings Limited (RDY) ORDINARY FULLY PAID |
Information Technology |
$185 |
Half Year Accounts - Media Release
|
26 Feb 2026 8:35AM |
$1.730 |
$1.500 |
fallen by
13.29%
|
|
RDY - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 5.6% to $61.6 million in 1H FY26.
- Subscription revenue represents 84% of total revenue.
- Significant government win with a 10-year contract with Skills Tasmania.
- Major justice sector contract with the Workplace Injury Commission.
- Investment in R&D accounted for 29.5% of revenue.
- AI innovations are a strategic focus, with AI-driven hiring showing positive outcomes.
- Challenges included elevated churn and a cyber incident impacting performance.
- Refreshed strategy: Clearer, Faster, Stronger.
- Revised FY26 revenue guidance to $125-127 million, FY27 targets withdrawn.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$5,815 |
Update - Notification of buy-back - ANN
|
26 Feb 2026 8:34AM |
$32.020 |
$41.440 |
risen by
29.42%
|
|
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$48 |
1H FY26 Results Announcement
|
26 Feb 2026 8:34AM |
$0.260 |
$0.250 |
fallen by
3.85%
|
|
GTN - Price-sensitive ASX Announcement
Full Release
Key Points
- GTN Limited announced 1H FY26 results, reporting financial challenges.
- Implemented cost base reset and market repositioning strategies.
- Returned $43.9 million to shareholders, maintaining strong liquidity.
- Revenue of $82.5 million and adjusted EBITDA of $5.8 million, indicating declines.
- A $41.5 million non-cash impairment charge recognized.
- Declared an interim dividend of $0.01 per share, unfranked.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$51 |
Half Year Report and Appendix 4D
|
26 Feb 2026 8:34AM |
$0.032 |
$0.026 |
fallen by
18.75%
|
|
SNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Syntara Limited reported a significant decline in revenues and an increase in losses for the half-year ended 31 December 2025.
- Revenues from ordinary activities decreased by 36.9% to $3,472,000.
- The loss from continuing operations after tax increased by 117.6% to $6,051,000.
- No dividends were paid, recommended, or declared during the period.
- The company's lead drug candidate, amsulostat (SNT-5505), progressed in clinical development for conditions like myelofibrosis and myelodysplastic syndromes.
- Syntara gained Orphan Drug Designation from the European Medicines Agency, ensuring market exclusivity for amsulostat in Europe.
- The company started a Phase 2 study in Australia for amsulostat in myelodysplastic syndromes, supported by funding from the Australian Government.
- Total assets decreased to $14,055,000 from $21,443,000 as of 30 June 2025.
- Net cash outflow from operating activities was $4,496,000 for the half-year.
- There was no audit qualification or review dispute for the financial statements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| QuickFee Limited (QFE) ORDINARY FULLY PAID |
Financials |
$30 |
Notice under section 708A(5) of the Corporations Act 2001
|
26 Feb 2026 8:34AM |
$0.079 |
$0.078 |
fallen by
1.27%
|
|
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$48 |
Dividend/Distribution - GTN
|
26 Feb 2026 8:33AM |
$0.260 |
$0.250 |
fallen by
3.85%
|
|
| xReality Group Ltd (XRG) ORDINARY FULLY PAID |
Consumer Discretionary |
$48 |
XRG Investor Presentation HY26
|
26 Feb 2026 8:33AM |
$0.051 |
$0.064 |
risen by
25.49%
|
|
XRG - Price-sensitive ASX Announcement
Full Release
Key Points
- Record half-year performance driven by Operator XR product.
- Total revenue for H1 FY26 increased to $10.4 million, up 41% year-over-year.
- Net profit after tax of $0.7 million, an improvement of $1.7 million from previous period.
- EBITDA increased to $2.6 million, up 190% from year-over-year.
- Annual recurring revenue from Operator XR grew to $6.2 million.
- Sales pipeline increased to $63 million, up 107% year-to-date.
- Expansion into U.S. and other high-growth global markets.
- Launch of Counter-Drone capability to enhance product offerings.
- Strategic focus on Operator XR as core growth engine.
- Exit from legacy VR entertainment operations almost complete.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Control Bionics Limited (CBL) ORDINARY FULLY PAID |
Health Care |
$31 |
Investor call presentation
|
26 Feb 2026 8:32AM |
$0.060 |
$0.058 |
fallen by
3.33%
|
|
| xReality Group Ltd (XRG) ORDINARY FULLY PAID |
Consumer Discretionary |
$48 |
Appendix 4D and Half Year Financial Report
|
26 Feb 2026 8:32AM |
$0.051 |
$0.064 |
risen by
25.49%
|
|
XRG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 41% to $10,437,227.
- Profit after tax was $733,205.
- No dividends declared for the half-year.
- Net tangible assets per security increased to $0.006.
- Continued investment in product capability and content development.
- Shift towards a software-led, recurring revenue model.
- Strong operating cash flow and successful debt repayment.
- Directors confident in the Group's financial stability and future operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GTN Limited (GTN) ORDINARY FULLY PAID |
Communication Services |
$48 |
Appendix 4D and Half Year Financial Statements
|
26 Feb 2026 8:32AM |
$0.260 |
$0.250 |
fallen by
3.85%
|
|
GTN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss of $40.9 million reported for the half-year ending 31 December 2025.
- Revenue declined by 14.7% to $82.5 million.
- Impairment charge of $41.5 million affected financial results.
- Brazil was the only market with revenue growth.
- A $43.9 million capital return was executed.
- Interim dividend declared at $0.01 per share, unfranked.
- Auditor confirmed compliance with legislative and professional standards.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austin Engineering Limited (ANG) ORDINARY FULLY PAID |
Industrials |
$109 |
Appendix 4D
|
26 Feb 2026 8:31AM |
$0.265 |
$0.175 |
fallen by
33.96%
|
|
ANG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations down 3.0% to AUD 170.3 million.
- EBITDA from continuing operations down 63.0% to AUD 8.0 million.
- Profit from continuing operations after income tax down 85.4% to AUD 2.0 million.
- Profit after tax attributable to members down 86.1% to AUD 1.8 million.
- Interim dividend of 0.3 cents per share declared, fully franked.
- Net tangible assets per ordinary share decreased to 18.53 cents.
- No acquisitions, associates, or joint ventures were reported.
- Financial report reviewed with an unqualified report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$417 |
CVW Investor Presentation - HY26
|
26 Feb 2026 8:31AM |
$0.625 |
$0.650 |
risen by
4%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported underlying NPAT from continuing operations is $22.1 million.
- In-force premiums increased to $436.0 million, up 13%.
- Clearview's balance sheet reflects $806.5 million in total assets and $348.4 million in net assets.
- A $120 million Tier 2 note was issued in March 2025, with $75 million redeemed in November 2025.
- The ClearChoice product now constitutes 31% of the in-force portfolio.
- The presentation provides an economic impact analysis on AASB 17 liability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImpediMed Limited (IPD) ORDINARY FULLY PAID |
Health Care |
$18 |
FY26 Half Year Financial Results
|
26 Feb 2026 8:30AM |
$0.019 |
$0.005 |
fallen by
73.68%
|
|
IPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue for H1 FY26 was $7.5 million, up 25% compared to the prior period.
- Gross margin remained strong at 87%.
- Significant improvement in U.S. reimbursement coverage to 93%.
- Annual Recurring Revenue increased to $14.4 million, up 15%.
- SOZO® Core Business Total Contracted Value rose to $8.7 million, up 9%.
- Entry into Heart Health market with initial sales in Texas.
- Launch in weight management and body composition market targeting a A$650 million market.
- Expanding U.S. pipeline with 700 potential units, representing over US$35 million in potential contract value.
- Focus on capital management and operational efficiency for growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ImpediMed Limited (IPD) ORDINARY FULLY PAID |
Health Care |
$18 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 8:30AM |
$0.019 |
$0.005 |
fallen by
73.68%
|
|
IPD - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from ordinary activities increased by 25% to $7,516,000.
- Net loss attributable to members increased by 25% to $12,349,000.
- No dividends were declared or paid during this period.
- The SOZO product line remains a primary focus for revenue.
- The company continues to rely on raising additional capital and maintaining borrowing facilities.
- Costs in salaries, benefits, and operational areas are high contributing to the loss.
- The financial statements comply with AASB 134 and Corporations Act 2001.
- The report was approved for release by the Board of ImpediMed Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$417 |
CVW Market Release HY26 Results
|
26 Feb 2026 8:30AM |
$0.625 |
$0.650 |
risen by
4%
|
|
CVW - Price-sensitive ASX Announcement
Full Release
Key Points
- Life Insurance Underlying NPAT up 59% to $24.1m
- Group Underlying NPAT up 77% to $22.1m
- Group Underlying EPS increased to 3.5 cents per share
- Gross premium income rose by 13% to $215.6m
- New business growth increased by 29%
- Simplification and transformation strategy completed
- ClearView operating on a single cloud-based insurance platform
- ClearView's net assets are $348.4m
- A scheme of arrangement with Zurich Financial Services announced
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$3,053 |
Net Tangible Asset Backing
|
26 Feb 2026 8:30AM |
$4.400 |
$4.810 |
risen by
9.32%
|
|
Call 1300 880 160
Start a chat
Schedule a call
